TrialPath
Recruiting

Topical Insulin for Glaucoma

NCT05206877 · Stanford University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Topical Insulin for Glaucoma and Optic Neuropathies
About this study
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Eligibility criteria
Inclusion Criteria: * Capable to provide informed consent * Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen. * Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched. Exclusion Criteria: * Pregnant or breastfeeding woman * Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.) * Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus * Inability to perform reliable visual field * Unable to provide informed consent * Unable to complete the tests and follow-ups required by the study
Study design
Enrollment target: 52 participants
Allocation: randomized
Masking: single
Age groups: adult, older_adult
Timeline
Starts: 2022-04-01
Estimated completion: 2026-12-31
Last updated: 2026-10-20
Interventions
Drug: Insulin, 4 unitsDrug: Insulin, 20 unitsDrug: insulin, 4 units twice dailyDrug: insulin, 20 units twice dailyDrug: insulin, 4 units three times dailyDrug: insulin, 20 units three times daily
Primary outcomes
  • • Number of Participants with Treatment-Related Adverse Events (During treatment period, difference from baseline to post-treatment up to 2 months)
Sponsor
Stanford University · other
Contacts & investigators
ContactStudy Team · contact · glaucomatrials@stanford.edu · 650-497-5942
InvestigatorJeffrey L Goldberg, MD, PhD · principal_investigator, Stanford University
All locations (1)
Byers Eye Institute at Stanford UniversityRecruiting
Palo Alto, California, United States
Topical Insulin for Glaucoma · TrialPath